Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead..
Metabolism. 78, A4-A9.
(2018). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity..
Helicobacter. 20(6), 405-9.
(2015). Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone..
Osteoporos Int. 22(1), 363-7.
(2011). Adipokines in nonalcoholic fatty liver disease..
Metabolism. 65(8), 1062-79.
(2016). Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023). Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis..
Curr Med Chem.
(2023). Visual vignette. Anaplastic thyroid carcinoma..
Endocr Pract. 18(1), 108.
(2012). Selenium and selenoprotein P in nonalcoholic fatty liver disease..
Hormones (Athens). 19(1), 61-72.
(2020). Homocysteine in nonalcoholic steatohepatitis: A reply..
Eur J Intern Med. 35, e40-e41.
(2016). Serum alpha-fetoprotein in patients with nonalcoholic fatty liver disease..
Eur Rev Med Pharmacol Sci. 17(17), 2411-2.
(2013). Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis..
Metabolism. 60(3), 313-26.
(2011). Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways..
Med Hypotheses. 72(5), 610.
(2009). Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index..
Ann Hepatol. 12(5), 749-57.
(2013). Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement..
Metabolism. 96, 66-82.
(2019). Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis..
J Clin Gastroenterol. 44(3), 229-30; author reply 230-1.
(2010). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). Aromatase inhibitors in post-menopausal endometriosis..
Reprod Biol Endocrinol. 9, 90.
(2011). Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management..
Metabolism. 155936.
(2024). Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort..
Horm Metab Res. 51(2), 134-140.
(2019). Leptin in health and disease: facts and expectations at its twentieth anniversary..
Metabolism. 64(1), 5-12.
(2015). Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy..
Helicobacter. 24(3), e12588.
(2019). The use of demographic, ultrasonographic and scintigraphic data in the diagnostic approach of thyroid nodules..
Exp Clin Endocrinol Diabetes. 117(4), 159-64.
(2009). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023). Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy..
J Otolaryngol Head Neck Surg. 39(5), 532-41.
(2010).